Electrocardiographic and Hemodynamic Effects of a Multicomponent Dietary Supplement Containing Ephedra and Caffeine: A Randomized Controlled Trial

JAMA

Volumn 291, Issue 2, 2004, Pages 216-221

  McBride, Brian F ^a,c   Karapanos, Angeliki K ^a   Krudysz, Agnes ^a   Kluger, Jeffrey ^a,b,c   Coleman, Craig I ^a,c   White, C Michael ^a,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE PLUS EPHEDRA EXTRACT; EPHEDRA EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTROCARDIOGRAM; EPHEDRA; FEMALE; HEMODYNAMIC MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 0345831912     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.2.216     Document Type: Article

References (33)

1. Agency for Healthcare Research and Quality. Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects. Washington, DC: US Dept of Health and Human Services; 2001.
2. Cleland RL, Gross WC, Koss LD, Daynard M, Muoio KM. Weight Loss Advertising: An Analysis of Current Trends. Washington, DC: Federal Trade Commission; 2002.
3. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE. Goodman and Gilmans' The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:215-268.
4. Undem BJ, Lichtenstein LM. Drugs used in the treatment of asthma. In: Hardman JG, Limbird LE. Goodman and Gilmans' The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:733-754.
5. Miller LG, Hume A, Harris IM, et al. ACCP white paper on herbal products. Pharmacotherapy. 2000;20:877-891.
6. IRI: Overall supplement sales slightly up. Available at: http://www.naturalproductsinsider .com/articles/231news1.html. Accessed September 3, 2003.
7. Metabolife 356 (product information. Available at: http://www.metabolife.com/products/productsDetail .jsp?id=138. Accessed November 4, 2003.
8. US Department of Health and Human Services. Dietary supplements containing ephedrine alkaloids. Federal Register. 2000;65:17510-17511.
9. Discount Anabolics. Muscletech Hydroxycut with ephedra. Available at: http://www.discountanabolics .com/page/DA/PROD/MUSCLETECH/MHW. Accessed September 5, 2003.
10. Musclesurf.com (anonymous). Xenadrine RFA-1. Available at: http://www.musclesurf.com /xenadrinerfa1.html. Accessed September 5, 2003.
11. Nutramerica. TrimSpa ingredients. Available at: http://www.trimspa.com/products/weight2_2 .shtml. Accessed September 5, 2003.
12. Tran HT, Fan C, Tu WQ, Kertland H, Kluger J, Chow MSS. QT measurement, a comparison of three simple methods. Ann Noninvasive Electrocardiol. 1998;3:228-231.
13. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:23B-25B.
14. Drazner M, Thompson B, Rosenberg P, et al. Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2002;89:993-995.
15. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QT interval: how long is prolonged? J Am Coll Cardiol. 1996;27:76-83.
16. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
17. Caron MF, Hotsko AL, Robertson S, Mandybur L, Kluger J, White CM. Electrocardiographic and hemodynamic effects of Panax Ginseng. Ann Pharmacother. 2002;36:758-763.
18. Committee for Proprietary Medicinal Products (CPMP). Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Noncardiovascular Medicinal Products. London, England: Center for Proprietary Medicinal Products; 1997.
19. US Food and Drug Administration. Preliminary concept paper on the clinical evaluation of the QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http: //www.fda.gov/cder/calendar/meeting/qt4jam .pdf. Accessed November 4, 2003.
20. Wang SH, Lin CY, Huang TY, Wu WS, Chen CC, Tsai SH. QT interval effects of cisapride in the clinical setting. Int J Cardiol. 2001;80:179-183.
21. Gillen MS, Miller B, Chaikin P, Morganroth J. Effect of supratherapeutic doses of ebastine and terfenadine on the QTc interval. Br J Clin Pharmacol. 2001;52:201-204.
22. van Harrst AD, van't Klooster GA, van Gerven JM, et al. The influence of ciaspride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998;64:542-546.
23. Honig PK, Worhtam DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
24. Ziprasidone (Geodon) package insert. Available at: http://www.pfizer.com/download/uspi_geodon.pdf. Accessed July 28, 2003.
25. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.
26. Sotalol (Betapace) package insert. Available at: http://www.betapace.com. Accessed November 4, 2003.
27. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 2000;139:814-819.
28. Dilaveris PE, Gialofos EJ, Sideris SK, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J. 1998;135:733-738.
29. Zaman AG, Alamgir F, Richens T, Williams R, Rothman MT, Mills PG. The role of signal averaged P-wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary by-pass surgery. Heart. 1997;77:527-531.
30. Gardner SF, Franks AM, Gurley BJ, Haller CA, Singh BK, Mehta JL. Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on Holter monitoring and hemostatic parameters in healthy volunteers. Am J Cardiol. 2003;91:1510-1513.
31. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537-45.
32. Hohnloser SH. Proarrhythmia with class III anti-arrhythmic drugs: types, risks, and management. Am J Cardiol. 1997;80:82G-89G.
33. Ammar R, Song JC, Kluger J, White CM. Evaluation of electrocardiographic and hemodynamic effects of caffeine with acute dosing in heathy volunteers. Pharmacotherapy. 2001;21:437-442.